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Original Article
Purpose: The aim of this study was to analyze the patterns of care and treatment outcomes in patients with primary thyroid 
lymphoma (PTL) in a single institution.
Materials and Methods: Medical records of 29 patients with PTL treated between April 1994 and February 2012 were 
retrospectively reviewed. Diagnosis was confirmed by biopsy (n = 17) or thyroidectomy (n = 12). Treatment modality and outcome 
were analyzed according to lymphoma grade.
Results: The median follow-up was 43.2 months (range, 3.8 to 220.8 months). The median age at diagnosis was 57 years (range, 
21 to 83 years) and 24 (82.8%) patients were female. Twenty-five (86.2%) patients had PTL with stage IEA and IIEA. There were 8 
(27.6%) patients with mucosa-associated lymphoid tissue (MALT) lymphoma and the remaining patients had high-grade lymphoma. 
Patients were treated with surgery (n = 2), chemotherapy (n = 7), radiotherapy (n = 3) alone, or a combination of these methods (n 
= 17). Treatment modalities evolved over time and a combination of modalities was preferred, especially for the treatment of high-
grade lymphoma in recent years. There was no death or relapse among MALT lymphoma patients. Among high-grade lymphoma 
patients, 5-year overall survival (OS) and 5-year progression-free survival (PFS) were 75.6% and 73.9%, respectively. Complete 
remission after initial treatment was the only significant prognostic factor for OS (p = 0.037) and PFS (p = 0.003).
Conclusion: Patients with PTL showed a favorable outcome, especially with MALT lymphoma. Radiotherapy alone for MALT 
lymphoma and chemotherapy followed by radiotherapy for high-grade lymphoma can be effective treatment options for PTL.
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Introduction
Primary thyroid lymphoma (PTL) is a rare malignancy with an 
incidence of 1% to 5% of all thyroid malignancies and 1% to 
2% of all extranodal lymphomas [1,2]. In Korea, its prevalence 
is decreasing to 0.1% of all thyroid carcinoma as the detection 
of papillary microcarcinoma is increasing [3].
  PTL is more common in mid- to older-aged women, with 
a peak incidence in the late 60s. The majority of PTLs are 
non-Hodgkin lymphoma of B cell origin; diffuse large B cell 
lymphoma (DLBCL) is the most common histologic subtype 
followed by mucosa-associated lymphoid tissue (MALT) 
lymphoma [4,5].
  Chronic lymphocytic thyroiditis (Hashimoto thyroiditis) 
is associated with development of PTL, particularly MALT 
lymphoma [5-7]. MALT lymphoma generally arises in lymphoid 
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tissue as a result of chronic inflammation, but the exact 
mechanism of malignant transformation from Hashimoto 
thyroiditis to MALT lymphoma is unknown. High-grade 
lymphomas including DLBCL, T-cell lymphoma, and Burkitt 
lymphoma show a more aggressive clinical course than low-
grade lymphomas such as MALT lymphoma.
  Radiotherapy (RT) alone provides an excellent outcome 
for MALT lymphoma of the conjunctiva and stomach, and 
combination chemotherapy (CTx) followed by consolidation 
RT is standard for high-grade lymphoma [8]. However, no 
standard treatment is established for PTL and there is a lack 
of randomized or prospective studies focusing on treatment 
outcome of PTL due to the rarity of the disease. 
  In this study, we aimed to analyze the patterns of care during 
the last two decades and treatment outcomes in patients with 
PTL in a tertiary hospital setting. 
Materials and Methods
Thirty-six patients with PTL who were treated in Severance 
Hospital between April 1994 and February 2012 were 
investigated retrospectively. Seven patients were excluded as 
they had double primary cancers, refused treatment, and died 
before response evaluation, leaving a total of 29 patients for 
retrospective analysis. 
  Because of the low accuracy of diagnosis with fine-needle 
aspiration (FNA), diagnosis was confirmed by thyroid biopsy 
or thyroidectomy. The Ann Arbor staging system was used for 
clinical staging; stage IE, disease confined to the thyroid; stage 
IIE, disease confined to the thyroid gland and regional lymph 
nodes above the diaphragm; stage IIIE, disease confined to the 
thyroid and lymph nodes above and below the diaphragm and/
or spleen; and stage IV, disseminated nodal and/or additional 
extranodal involvement. 
  Tumor responses were evaluated using updated response 
criteria from the International Harmonization Project, 
incorporat ing positron emiss ion tomography (PET) , 
immunohistochemistry, and flow cytometry for high-grade 
lymphoma. Complete remission (CR) was defined as complete 
disappearance of all detectable evidence of disease; PET was 
negative regardless of residual tumor size in patients whose 
PET scan was positive before treatment [9]. Responses after 
initial treatment were described in patients who did not 
receive total thyroidectomy and relapse/progression was 
evaluated in all patients. Relapse/progression was defined as 
the reappearance of disease after CR, the appearance of new 
disease, or an increase in tumor size. Toxicity was graded using 
the Common Terminology Criteria for Adverse Events ver. 4.0.
  Overall survival (OS) was defined as the time between the 
diagnosis and death or last follow-up for surviving patients 
and progression-free survival (PFS) was defined as the time 
from the end of treatment to the time of disease progression 
in patients evaluable for relapse/progression. 
  Statistical analysis was performed using SPSS ver. 20.0 
software (IBM, Armonk, NY, USA). OS and PFS were calculated 
using the Kaplan-Meier method. A p-value <0.05 was 
considered statistically significant.
Results
The median follow-up for all patients was 43.2 months (range, 
Table 1. Patient and tumor characteristics
Characteristic
MALT  
lymphoma 
(n = 8)
High-grade 
lymphoma
 (n = 21)
Age (yr), median (range)
   ≤60
   >60
Sex
   Female
   Male
ECOG performance status
   0
   1
   2
Hashimoto disease
   No
   Yes
Stage
   IEA
   IIEA
   IIIEA
   IVEA
Diagnosis
   Biopsy
   Surgery
Pathologic subtype (high-grade)
   DLBCL
Malignant lymphoma arising 
MALT lymphoma
   Burkitt lymphoma
62 (35–83)
4 (50.0)
4 (50.0)
 
7 (87.5)
1 (12.5)
 
5 (62.5)
3 (37.5)
0
 
4 (50.0)
4 (50.0)
 
5 (62.5)
3 (37.5)
0
0
 
4 (50.0)
4 (50.0)
 
-
-
 
-
54 (21–72)
13 (61.9)
8 (38.1)
 
17 (81.0)
4 (19.0)
 
14 (66.7) 
6 (28.6)
1 (4.8)
 
11 (52.4)
10 (47.6)
 
10 (47.6) 
7 (33.3)
1 (4.8)
3 (14.3)
 
13 (61.9)
8 (38.1)
 
17 (81.0) 
3 (14.3)
 
1 (4.8)
Values are presented as number (%).
ECOG, Eastern Cooperative Oncology Group; MALT, mucosa-as-
sociated lymphoid tissue; DLBCL, diffuse large B cell lymphoma.
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3.8 to 220.8 months). Eight (27.6%) patients were diagnosed as 
MALT lymphoma and 21 (72.4%) were diagnosed as high-grade 
lymphoma. The patient and tumor characteristics are shown 
in Table 1, and the treatment characteristics are described in 
Table 2. Fig. 1 summarizes initial treatments administered to 
patients with MALT lymphoma and high-grade lymphoma and 
treatment response.
1. MALT lymphoma
The median age of patients with MALT lymphoma at diagnosis 
was 62 years (range, 35 to 83 years) and 7 (87.5%) patients 
were female. Four of eight patients (50%) had clinical or 
histological evidence of Hashimoto thyroiditis. The most 
common symptom in patients was palpable or growing 
thyroid mass and no patients in this study presented with B 
symptoms.
  All patients had early-stage lymphoma and there were 5 and 
3 patients with stage I and II, respectively. 
  Four patients (50%) underwent surgery as primary treatment, 
and among these patients, 1 patient received no adjuvant 
treatment after total thyroidectomy and three other patients 
received RT or CTx followed by RT for adjuvant treatment. Four 
patients were diagnosed with biopsy and treated with RT or 
CTx alone. The median total dose was 30.6 Gy (range, 30.6 to 
45 Gy). A dose of 45 Gy was prescribed in 1 patient who was 
diagnosed as high-grade MALT lymphoma. The RT volume 
included the thyroid and involved node area. Prophylactic 
irradiation to the bilateral neck node or upper mediastinum 
was done in most patients. Two patients with stage I received 
radiation to the upper mediastinal node area and only 1 
patient received radiation to the thyroid alone. CTx was used in 
2 patients.
  Treatments have changed over time. In recent years, surgery 
has not been the main diagnostic and therapeutic tool; RT 
after diagnosis confirmed by thyroid biopsy has been the 
main treatment. In 2 patients treated with surgery after 2006, 
surgery was palliative, not diagnostic, to relieve the pressure 
symptom due to the thyroid mass, and lymphoma was 
diagnosed in the pathology specimen.
  Treatment outcome in patients with MALT lymphoma was 
excellent (Fig. 1A). Except 2 patients who received total 
thyroidectomy, other 6 patients showed complete response 
after initial treatment. During follow-up period, 7 patients are 
alive with no evidence of disease and 1 patient is alive with 
unknown disease status due to follow-up loss.
  Treatment-related toxicities are shown in Table 3. There was 
no greater than grade 3 toxicity. Except for 6 patients who 
were under thyroid hormone replacement therapy before 
diagnosis of lymphoma or after thyroidectomy, 1 patient had 
newly diagnosed hypothyroidism at 2 years 3 months after RT.
2. High-grade lymphoma
This group included DLBCL, Burkitt lymphoma, and malignant 
lymphoma arising MALT lymphoma, and the number of 
patients in each subtype was 17, 1, and 3, respectively. In 6 
patients with DLBCL, MALT lymphoma was mixed with DLBCL. 
The number of patients with early stage (stage I and II) was 17 
(80.9%), and 3 patients were diagnosed as stage IV. 
  Similar to MALT lymphoma, patterns of care evolved over 
time for high-grade lymphoma. Before 2006, the mainstay 
of treatment was surgery, and 8 of 10 patients received 
thyroidectomy. Surgery in these 8 patients was followed 
Table 2. Treatment characteristics
Characteristic
MALT lymphoma 
(n = 8)
High-grade  
lymphoma
(n = 21)
Treatment
   Surgery
   Surgery + CTx
   Surgery + RT
   Surgery + CTx + RT
   CTx
   RT
   CTx + RT
Surgery
   No
   Total thyroidectomy
   Other surgery
CTx
   No
   R-CHOP regimen
   Other regimen
   Cycle, median (range)
RT
   No
   Yes
   Total dose (Gy), median 
  (range)
   Fraction dose (Gy),  
  median (range)
 
1 (12.5)
0
2 (25.0)
1 (12.5)
1 (12.5)
3 (37.5)
0
 
4 (50.0)
2 (25.0)
2 (25.0)
 
6 (75.0)
0
2 (25.0)
6
2 (25.0)
6 (75.0)
30.6 (30.0–45.0)
 
1.8 (1.8–2.0)
 
 
1 (4.8) 
3 (14.3)
4 (19.0)
1 (4.8)
6 (28.6)
0
6 (28.6)
 
12 (57.1)
3 (14.3)
6 (28.6)
 
5 (23.8)
11 (52.4)
5 (23.8)
 5.5 (1–8)
10 (47.6)
11 (52.4)
42.5 (30.6–45.0)
 
1.8 (1.5–2.0)
 
Values are presented as number (%).
CTx, chemotherapy; RT, radiotherapy; R-CHOP, rituximab, cy-
clophosphamide, doxorubicin, vincristine, prednisone; MALT, 
mucosa-associated lymphoid tissue.
Hyejung Cha, et al
180 www.e-roj.org http://dx.doi.org/10.3857/roj.2013.31.4.177
by adjuvant treatment except for the case of 1 patient, and 
adjuvant treatment included chemotherapy alone (n = 2), RT 
alone (n = 4), or chemotherapy followed by RT (n = 1). After 
2006, only 1 patient received surgery and the other 10 patients 
were diagnosed with biopsy and received chemotherapy as an 
initial treatment. RT was given with adjuvant aim after surgery 
(n = 5) or a consolidation aim after chemotherapy (n = 6). A 
median of 42.5 Gy (range, 30.6 to 45 Gy) was prescribed and 
the dose for 6 of 11 patients was 45 Gy. The RT volume was 
the same as that for MALT lymphoma. Bilateral neck node 
irradiation was done in all patients regardless of neck node 
involvement, and 4 patients with stage I received radiation to 
the upper mediastinum. One patient with stage IVEA gained 
CR after CTx and received consolidation RT to the thyroid and 
neck node area after a discussion with a hematologist. Sixteen 
patients (76.2%) were treated with CTx and rituximab plus 
cyclophosphamide, doxorubicin, vincristine, and prednisone 
(R-CHOP) was the most common regimen.
  Initial treatments, treatment response, and current status 
were shown in Fig. 1B. Except for 3 patients who received 
Fig. 1. Patterns of care and treatment 
outcome of mucosa-associated 
lymphoid tissue (MALT) lymphoma 
(A) and high-grade lymphoma (B). 
Treatments were heterogeneous, but 
diagnosis by biopsy and chemothe-
rapy and/or radiotherapy has been 
the mainstay in recent years. CTx, 
chemotherapy; RT, radiotherapy; CR, 
complete remission; Tx, treatment; 
NED, no evidence of disease; PD, 
progression disease; SD, stable disea-
se.
Table 3. Treatment-related toxicity
MALT lymphoma High-grade lymphoma
Grade 3 Grade 4 Grade 5 Grade 3 Grade 4 Grade 5
Hematologic
   Neutropenia
   Anemia
   Thrombocytopenia
Non-hematologic
   Esophagitis
   Nausea
   Skin reaction
   Oral mucositis
   Sore throat
 
0
0
0
 
0
0
0
0
0
 
0
0
0
 
0
0
0
0
0
 
0
0
0
 
0
0
0
0
0
 
1
5
0
 
2
0
0
0
0
 
12
0
2
 
0
0
0
0
0
 
1a)
0
0
 
0
0
0
0
0
a)Neutropenia developed after the second cycle of chemotherapy and the patient died from pneumonia followed by septic shock. This 
patient was not included in the analysis due to death before response evaluation.
181
 Outcomes of primary thyroid lymphoma
www.e-roj.orghttp://dx.doi.org/10.3857/roj.2013.31.4.177
total thyroidectomy, CR, PR, SD, and PD after initial treatment 
were observed in 15, 1, 1, and 1 patients, respectively. Relapse 
occurred in 5 patients and in 1 patient the disease status was 
unknown due to death. 
  The median OS was not reached and OS rates at 5-year and 
10-year were 75.6% and 56.7%, respectively (Fig. 2A). Seven 
(24.1%) patients were dead at the time of analysis and 14 
patients were alive without disease. CR after initial treatment 
(Fig. 3A, p < 0.0001) and no relapse (Fig. 3B, p = 0.014) were 
statistically significant in univariate analysis. In multivariate 
analysis, CR after initial treatment was the only significant 
prognostic factor (p = 0.037). Three of 7 patients died of 
disease unrelated to lymphoma. Disease-specific survival at 
5-year and 10-year was 85.0% and 74.4%, respectively.
  Relapse after CR or partial response occurred in 4 patients 
and progression after initial treatment showed in 1 patient. 
Details of patients with treatment failure are shown in Table 4. 
One patient was treated with total thyroidectomy and adjuvant 
RT and relapse on stomach was occurred after 2 years. The 
median PFS was not reached and 5-year and 10-year survival 
rates were 73.9% and 63.4%, respectively. Locoregional relapse 
was the main pattern of relapse. CR after initial treatment was 
associated with better PFS (p = 0.003). 
  Salvage treatments were mainly chemotherapy. After salvage 
treatment, CR was achieved in 3 of 4 patients who could be 
evaluated for response. One patient was treated in another 
Fig. 2. (A) Overall survival (OS) and (B) progression-free survival (PFS). Both median OS and PFS not reached. The patients with mucosa-
associated lymphoid tissue (MALT) lymphoma were all alive and didn’t show a relapse except 1 patient who was lost follow-up. In high-
grade lymphoma, 5- and 10-year OS rates were 75.6% and 56.7%, respectively, and 5- and 10-year PFS rates were 73.6% and 63.0%, 
respectively. 
Fig. 3. Overall survival (OS) in patients with high-grade lymphoma. (A) Complete remission (CR) after initial treatment was associated 
with OS (p = 0.039). (B) Patients with a relapse/progression showed worse survival than patients without relapse/progression (p = 0.023). 
Hyejung Cha, et al
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hospital and the treatment regimen and response were 
unknown. The patient died 5 months after relapse. Another 
patient whose final tumor response was unknown had relapsed 
in the RT field 1 month after completion of RT. Additionally, 
boost RT of 20 Gy in 10 fractions to the relapse site was given 
and the palpable neck mass decreased during the treatment. 
However, further imaging study was not performed due to 
follow-up loss and she died 9 months after relapse. Two 
patients who gained CR after salvage treatment died due to 
pneumonia after autologous stem cell transplantation and 
progression of vaginal cancer diagnosed after treatment for 
PTL. Only one patient was alive without disease after relapse.
  Toxicity greater than grade 3 was observed in 15 patients, 
and most cases were hematologic toxicity due to CTx (Table 
3). In one patient, neutropenia developed after the second 
cycle of chemotherapy and the patient died of septic shock. 
This patient was not included in this study due to death 
before response evaluation. In 8 patients who were not under 
thyroid hormone replacement therapy, 2 had newly diagnosed 
hypothyroidism at 1 year 7 months after CTx, and 4 years 5 
months after CTx followed RT.
Discussion and Conclusion
The demographics of our study are consistent with those of 
previous studies [3,4,10]. PTL was predominant in mid-aged 
females. Growing thyroid mass was the main symptom and 
most patients had early stage (stage I and II) in both the MALT 
lymphoma and high-grade lymphoma groups. DLBCL was the 
most common histologic subtype. 
  Although FNA is the first diagnostic investigation in 
patients with a thyroid mass, its accuracy for PTL has been 
reported in a wide range, from 25% to 90% [11-13]. Most 
cases of PTL have been reported to be associated with pre-
existing Hashimoto thyroiditis, especially MALT lymphoma. 
Cytological differentiation of low-grade MALT lymphoma 
and Hashimoto thyroiditis is difficult and a sampling error 
can yield false-negative results [3,14]. Adjunctive techniques, 
such as immunohistochemical staining, molecular techniques, 
flow cytometry, or polymerase chain reaction to detect a 
monoclonal immunoglobulin heavy chain have been proposed 
to improve the diagnostic rate of FNA. However, tissue biopsy 
is considered the gold standard for histologic diagnosis in 
PTL [14]. In the current study, only the patients who were 
diagnosed with tissue biopsy or thyroidectomy were included 
in order to remove interference from potential misdiagnosis in 
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determining clinical course of such rare disease as PTL.
  Due to the rarity of disease, there has been no prospective 
randomized trial on the treatment for PTL and the current 
recommendation on the treatment for PTL depends on 
histologic subtype [10,15]. For indolent subtype of PTL, single-
modality treatment with either surgery or RT was considered 
where combined modality of chemotherapy and RT was 
preferred for more aggressive subtypes. 
  The role of surgery in PTL is still controversial and its use 
for diagnosis and treatment has decreased over time. Graff-
Baker et al. [4] reported that the use of surgery for PTL has 
declined from 81% of patients in 1973 to 1987 to 61% in 
1997 to 2005 in the United States. Meyer-Rochow et al. 
[16] reported that the proportion of operations on patients 
with a histopathological diagnosis of PTL has significantly 
decreased and therapeutic thyroid procedures also decreased 
significantly during the study period. In the current study, 
surgery was not the main treatment option after 2006 and 
non-surgical treatment including CTx and/or RT, depending on 
histologic subtype, has become the mainstay of treatment in 
recent years. 
  Histologic subtype was associated with survival in previous 
studies [3]. There was no statistical significance in the 
current study due to the small number of patients, but MALT 
lymphomas showed more favorable outcome than high-grade 
lymphomas. All patients with MALT lymphoma obtained CR 
and they are all alive with no relapse. All 6 cases of relapse/
progression occurred in patients with high-grade lymphoma 
and 4 patients died from progression of disease.
  Local therapy such as surgery or RT alone was the preferred 
treatment for localized MALT lymphoma [10,17,18]. In the 
current study, treatment outcomes between surgery followed 
by adjuvant treatment and biopsy followed by definitive RT 
were not different and severe treatment-related toxicity was 
not observed. Thyroidectomy is an invasive procedure requiring 
thyroid hormone replacement. Therefore, RT could be an 
appropriate option for MALT lymphoma in patients confirmed 
by thyroid biopsy, and this is a mainstay of treatment in 
localized MALT lymphoma of thyroid.
  The optimal RT dose and volume for PTL has not been 
determined and varies among different institutions [10,17,19]. 
Harrington et al. [20] recommend extended field RT (EFRT) to 
a dose of 40 Gy for stage I PTL and chemotherapy followed 
by consolidation EFRT to a dose of 40 Gy for stage II–IV 
disease. Alzouebi et al. [10] reported that a low dose, such as 
24 Gy in 12 fractions is sufficient for localized PTL of indolent 
subtype and CTx followed by RT at higher doses is preferred 
for high-grade disease. In the current study, the median dose 
of 30.6 Gy was sufficient to obtain CR in MALT lymphoma. 
Higher RT dose at a median of 45.0 Gy was prescribed for 
high-grade lymphoma and 1 of 11 patients treated with RT 
showed relapse 1 month after completion of RT. One patient 
with stage IV received RT; she obtained CR after CTx and 
radiation was delivered only to the thyroid and neck node 
area after discussion with a hematologist. Relapse was not 
observed and she was alive at follow-up of 76 months. The 
RT volume included the thyroid and involved the node area 
and prophylactic irradiation to bilateral neck node or upper 
mediastinal node area was done in most patients. Patients 
with stage I who received radiation to the thyroid, neck, 
and upper mediastinal node area were treated with surgery 
followed by RT before 2006. In recent years, the RT volume 
involved the node area and bilateral neck node for prophylactic 
aim and treatment, and the upper mediastinal node area was 
considered when this area involved PTL. One patient with stage 
I MALT lymphoma was treated with RT alone to the thyroid 
only and 1 patient with stage II DLBCL received consolidation 
RT to the thyroid and ipsilateral nock node areas after CTx and 
no relapse occurred in these patients. Further study is needed 
to determine the optimal RT dose and volume for PTL. 
  The combination of CTx and RT for high-grade lymphoma 
was associated with improved survival in previous reports 
[10,19,21]. In the current study, patients who showed CR after 
more than 3 cycles of CTx followed by RT had not relapsed and 
1 locoregional relapse occurred in 5 patients who showed CR 
after chemotherapy alone. 
  There were no significant differences in survival according to 
patient age, stage, histologic subtype, or treatment modality, 
which was associated with survival in previous studies 
[3,6,9,10]. In the current study, CR after initial treatment was 
an only significant factor for OS and PFS, emphasizing the 
importance of initial treatment. A larger prospective trial is 
warranted for establishing consensus treatment for PTL. 
  In conclusion, patients with PTL showed a favorable 
outcome, especially with MALT lymphoma. RT alone can be an 
appropriate treatment option for localized MALT lymphoma. 
In high-grade lymphoma of the thyroid, locoregional relapse 
was a common pattern of failure, thus CTx followed by RT is 
thought to be more beneficial than CTx alone. CR after initial 
treatment was a significant factor for survival in high-grade 
lymphoma.
Hyejung Cha, et al
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